Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Atopic dermatitis (AD), a chronic, relapsing, inflammatory skin disease that is characterized by intense pruritus and eczematous lesions with up to 90% of patients presenting with mild to moderate disease. Current topical treatments for AD have not changed in over 15 years and are associated with safety concerns. In AD, overactivity of phosphodiesterase 4 (PDE4), leads to inflammation and disease exacerbation. Crisaborole Topical Ointment, 2%, is a novel, nonsteroidal, topical anti-inflammatory PDE4 inhibitor currently being investigated for the treatment of mild to moderate AD. Preliminary studies in children and adults demonstrated favorable efficacy and safety profiles. Crisaborole may represent an anti-inflammatory option that safely minimizes the symptoms and severity of AD and that can be used for both acute and long-term management.
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA, USA.
L T
LT
Zane
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA, USA.
S
S
Chanda
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA, USA.
K
K
Jarnagin
Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto, CA, USA.
D B
DB
Nelson
Veracity Clinical Research, Queensland, Australia.
L
L
Spelman
Henry Ford Health System, Detroit, MI, USA.
Lf Stein
LS
Gold
D000287:Administration, Topical; D000328:Adult; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001896:Boron Compounds / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D006801:Humans; D009824:Ointments; D058988:Phosphodiesterase 4 Inhibitors / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D009824:Ointments; D058988:Phosphodiesterase 4 Inhibitors; C543085:crisaborole
Crisaborole Topical Ointment, 2%; atopic dermatitis; cytokine; inflammation; pharmacokinetics; phosphodiesterase 4 inhibitor; pruritus; quality of life; topical calcineurin inhibitor; topical corticosteroid